A Phase 4 interventional study of semaglutide and oral glucose-lowering medications (commercially available) in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 10 that started in 2021, is one of 40 in phase 4, and was the 89th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,018 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 36th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2021, is one of 75 in phase 4, and was the 543rd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. The doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. The study will last for about 1 year. Participants will have 2 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit. In addition, the study personnel will contact participants up to 3 times during this period and to follow-up on information from participant doctors visits. Participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. All clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. The study team will collect information from these visits recorded in the medical chart. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Key inclusion criteria
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants are given tablets used in addition to metformin.
Drug: semaglutide
All participants are given tablets used in addition to metformin.
Drug: oral glucose-lowering medications (commercially available)
Oral administration The doctor will give a prescription for the medicine and tell how to take it.
Oral administration The doctor will give a prescription for the medicine and tell how to take it.
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c in percentage from week 0 to year 1 is presented
Time frame: Week 0, year 1
Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) (Yes /No)
Participants achieving HbA1c \< 7.0% (Yes /No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% and 'No' defines participants who did not achieve HbA1c \< 7.0 %.
Time frame: At year 1
Participants Achieving HbA1c Less Than or Equal to (≤) 6.5% (Yes/No)
Participants achieving HbA1c ≤ 6.5% (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c ≤ 6.5% and 'No' defines participants who did not achieve HbA1c ≤ 6.5%.
Time frame: At year 1
Participants Achieving HbA1c <7.0% or at Least 1.0%-Point Reduction in HbA1c (Yes/No)
Participants achieving HbA1c \< 7.0% or at least 1.0%-point reduction in HbA1c (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c and 'No' defines participants who did not achieve HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c.
Time frame: From Week 0 to year 1
Participants Achieving Greater Than or Equal to (≥) 5% Reduction in Body Weight (Yes/No)
Participants achieving ≥ 5% reduction in body weight (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved ≥ 5% reduction in body weight and 'No' defines participants who did not achieve ≥ 5% reduction in body weight.
Time frame: From week 0 to year 1
Participant Achieving Individualized HbA1c Target Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria (Yes/No)
Participants achieving individualized HbA1c target per HEDIS criteria (\< 8.0% if age ≥ 65 years or with defined comorbidities or otherwise \< 7.0%) (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved individualized HbA1c target per HEDIS criteria and 'No' defines participants who did not achieve individualized HbA1c target per HEDIS criteria.
Time frame: At year 1
Participant Achieving HbA1c ≤ Treatment Provider Defined Individualized Target (Yes/No)
Participant achieving HbA1c ≤ treatment provider defined individualized target (Yes/No) at year 1 is presented. 'Yes' defines participant who achieved HbA1c ≤ treatment provider defined individualized target and 'No' defines participant who did not achieve HbA1c ≤ treatment provider defined individualized target.
Time frame: At year 1
Relative Change in Body Weight (%)
Relative change in body weight from week 0 to year 1 is presented.
Time frame: Week 0, year 1
Change in Body Weight (Lbs)
Change in body weight in pounds (lbs) from week 0 to year 1 is presented.
Time frame: Week 0, year 1
Time to Treatment Intensification (add-on) or Change (Switch) in Terms of Events
Time to treatment intensification (add-on) or change (switch) in terms of events from week 0 to year 1 is presented.
Time frame: From week 0 to year 1
Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Relative Treatment Satisfaction Total Score
DTSQc relative treatment satisfaction total score measured at year 1 is presented. DTSQc are used to evaluate patient satisfaction with treatment. The measure consists of 8 items, 6 of which assess treatment satisfaction. Scores from the 6 treatment satisfaction items are summed to a total treatment satisfaction score, which ranges from -18 (much less satisfied) to +18 (much more satisfied).
Time frame: At year 1
The trial was conducted at 25 sites in the United States. One participant is counted in 'Completed' and not in 'Death in Reason for Not Completed' in Participant Flow as they died after completing the study and hence, not counted as non-completer.
| Milestone | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Started | 509 | 509 |
| Full analysis set | 509 | 509 |
| Safety analysis set | 500 | 492 |
| Completed | 449 | 448 |
| Not completed | 60 | 61 |
| Withdrew: Withdrawal by subject | 24 | 26 |
| Withdrew: Lost to follow-up | 29 | 30 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Site closure | 0 | 1 |
| Withdrew: Protocol specified withdrawal criterion met | 4 | 3 |
Change in HbA1c in percentage from week 0 to year 1 is presented
| Percentage change in HbA1c | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -1.20 ± 1.463 | -0.99 ± 1.516 |
Participants achieving HbA1c \< 7.0% (Yes /No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% and 'No' defines participants who did not achieve HbA1c \< 7.0 %.
| Participants | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Yes | 190 | 133 |
| No | 136 | 160 |
Participants achieving HbA1c ≤ 6.5% (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved HbA1c ≤ 6.5% and 'No' defines participants who did not achieve HbA1c ≤ 6.5%.
| Participants | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Yes | 127 | 68 |
| No | 199 | 225 |
Participants achieving HbA1c \< 7.0% or at least 1.0%-point reduction in HbA1c (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c and 'No' defines participants who did not achieve HbA1c \< 7.0% or reduction of at least 1.0%-point in HbA1c.
| Participants | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Yes | 239 | 180 |
| No | 87 | 113 |
Participants achieving ≥ 5% reduction in body weight (Yes/No) from week 0 to year 1 is presented. 'Yes' defines participants who achieved ≥ 5% reduction in body weight and 'No' defines participants who did not achieve ≥ 5% reduction in body weight.
| Participants | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Yes | 110 | 83 |
| No | 188 | 177 |
Participants achieving individualized HbA1c target per HEDIS criteria (\< 8.0% if age ≥ 65 years or with defined comorbidities or otherwise \< 7.0%) (Yes/No) at year 1 is presented. 'Yes' defines participants who achieved individualized HbA1c target per HEDIS criteria and 'No' defines participants who did not achieve individualized HbA1c target per HEDIS criteria.
| Participants | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Yes | 222 | 171 |
| No | 104 | 122 |
Participant achieving HbA1c ≤ treatment provider defined individualized target (Yes/No) at year 1 is presented. 'Yes' defines participant who achieved HbA1c ≤ treatment provider defined individualized target and 'No' defines participant who did not achieve HbA1c ≤ treatment provider defined individualized target.
| Participants | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Yes | 179 | 118 |
| No | 147 | 175 |
Relative change in body weight from week 0 to year 1 is presented.
| Percentage change in body weight | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Relative Change in Body Weight (%) | -4.00 ± 6.26 | -3.53 ± 6.49 |
Change in body weight in pounds (lbs) from week 0 to year 1 is presented.
| Lbs | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Change in Body Weight (Lbs) | -8.68 ± 14.23 | -7.75 ± 15.61 |
Time to treatment intensification (add-on) or change (switch) in terms of events from week 0 to year 1 is presented.
| Events | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Time to Treatment Intensification (add-on) or Change (Switch) in Terms of Events | 69 | 109 |
DTSQc relative treatment satisfaction total score measured at year 1 is presented. DTSQc are used to evaluate patient satisfaction with treatment. The measure consists of 8 items, 6 of which assess treatment satisfaction. Scores from the 6 treatment satisfaction items are summed to a total treatment satisfaction score, which ranges from -18 (much less satisfied) to +18 (much more satisfied).
| Score on a scale | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Relative Treatment Satisfaction Total Score | 12.28 ± 6.73 | 12.22 ± 6.18 |
Collected over From week 0 to week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Semaglutide | 3/500 (0.6%) | 51/500 (10.2%) | 81/500 (16.2%) |
| Other Oral Glucose-lowering Medication | 2/492 (0.4%) | 55/492 (11.2%) | 46/492 (9.3%) |
| Event | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| PneumoniaInfections and infestations | 2/500 | 5/492 |
| SepsisInfections and infestations | 2/500 | 5/492 |
| SyncopeNervous system disorders | 0/500 | 5/492 |
| FallInjury, poisoning and procedural complications | 4/500 | 3/492 |
| Chest painGeneral disorders | 2/500 | 3/492 |
| NauseaGastrointestinal disorders | 3/500 | 3/492 |
| Non-cardiac chest painGeneral disorders | 0/500 | 3/492 |
| Acute kidney injuryRenal and urinary disorders | 2/500 | 2/492 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/500 | 2/492 |
| Atrial fibrillationCardiac disorders | 1/500 | 2/492 |
| Event | Oral Semaglutide | Other Oral Glucose-lowering Medication |
|---|---|---|
| COVID-19Infections and infestations | 44/500 | 37/492 |
| NauseaGastrointestinal disorders | 38/500 | 10/492 |
Full analysis set included all randomised participants.
| Age, Continuous(Years) | Oral Semaglutide | Other Oral Glucose-lowering Medication | Total |
|---|---|---|---|
| Mean | 59.6 ± 11.9 | 59.8 ± 12.0 | 59.7 ± 12.0 |
| Sex: Female, Male(Participants) | Oral Semaglutide | Other Oral Glucose-lowering Medication | Total |
|---|---|---|---|
| Female | 231 | 237 | 468 |
| Male | 278 | 272 | 550 |
| Race/Ethnicity, Customized(Participants) | Oral Semaglutide | Other Oral Glucose-lowering Medication | Total |
|---|---|---|---|
| White | 373 | 366 | 739 |
| Black or African American | 65 | 68 | 133 |
| Asian | 44 | 36 | 80 |
| Other | 21 | 39 | 60 |
| Missing Race | 6 | 0 | 6 |
| Race/Ethnicity, Customized(Participants) | Oral Semaglutide | Other Oral Glucose-lowering Medication | Total |
|---|---|---|---|
| Hispanic or Latino | 91 | 102 | 193 |
| Non-Hispanic or Non-Latino | 408 | 404 | 812 |
| Missing Ethnicity | 10 | 3 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Sep 2021 to primary completion in Jun 2025, 45 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 45 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide